A detailed history of Balyasny Asset Management LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 17,000 shares of EXEL stock, worth $376,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,000
Previous 15,726 8.1%
Holding current value
$376,550
Previous $377,000 6.9%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $93,882 - $117,682
4,877 Added 44.95%
15,726 $377,000
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $7.87 Million - $9.4 Million
-413,420 Reduced 97.44%
10,849 $237,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $54.9 Million - $61.9 Million
-3,021,536 Reduced 87.69%
424,269 $8.11 Million
Q1 2023

May 15, 2023

BUY
$16.3 - $19.41 $50.7 Million - $60.4 Million
3,109,700 Added 925.22%
3,445,805 $66.9 Million
Q4 2022

Feb 14, 2023

SELL
$14.96 - $17.39 $1.34 Million - $1.55 Million
-89,359 Reduced 21.0%
336,105 $5.39 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $6.67 Million - $9.48 Million
425,464 New
425,464 $6.67 Million
Q2 2022

Aug 15, 2022

SELL
$17.44 - $23.16 $8.92 Million - $11.9 Million
-511,674 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $8.71 Million - $11.6 Million
511,674 New
511,674 $11.6 Million
Q4 2021

Feb 14, 2022

SELL
$15.84 - $21.88 $3.96 Million - $5.47 Million
-250,076 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$16.3 - $21.14 $9.57 Million - $12.4 Million
-587,256 Reduced 70.13%
250,076 $5.29 Million
Q2 2021

Aug 16, 2021

BUY
$17.95 - $25.56 $2.85 Million - $4.06 Million
158,661 Added 23.38%
837,332 $15.3 Million
Q1 2021

May 17, 2021

BUY
$20.53 - $25.22 $1.07 Million - $1.32 Million
52,352 Added 8.36%
678,671 $15.3 Million
Q4 2020

Feb 16, 2021

BUY
$18.39 - $24.8 $11.5 Million - $15.5 Million
626,319 New
626,319 $12.6 Million
Q2 2020

Aug 14, 2020

SELL
$16.46 - $27.42 $6.89 Million - $11.5 Million
-418,533 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$14.46 - $21.8 $1.08 Million - $1.63 Million
-74,985 Reduced 15.19%
418,533 $7.21 Million
Q4 2019

Feb 14, 2020

BUY
$15.15 - $18.89 $7.09 Million - $8.85 Million
468,256 Added 1853.6%
493,518 $8.7 Million
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $106,910 - $136,964
6,047 Added 31.47%
25,262 $447,000
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $178,339 - $233,169
-9,421 Reduced 32.9%
19,215 $411,000
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $236,650 - $298,952
12,074 Added 72.9%
28,636 $682,000
Q4 2018

Feb 14, 2019

SELL
$13.65 - $21.8 $33,715 - $53,846
-2,470 Reduced 12.98%
16,562 $326,000
Q3 2018

Nov 14, 2018

SELL
$15.87 - $22.4 $495,985 - $700,067
-31,253 Reduced 62.15%
19,032 $337,000
Q2 2018

Aug 14, 2018

SELL
$18.56 - $22.45 $10.5 Million - $12.7 Million
-566,533 Reduced 91.85%
50,285 $1.08 Million
Q1 2018

May 15, 2018

SELL
$22.15 - $31.89 $31.7 Million - $45.6 Million
-1,429,493 Reduced 69.86%
616,818 $13.7 Million
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $42.9 Million - $54.7 Million
1,768,764 Added 637.28%
2,046,311 $62.2 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $6.48 Million - $8.12 Million
277,547
277,547 $6.73 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.13B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.